Table 3.
PSA responders
| Patient ID |
Age | Gleason score |
Prior therapies | PSA baseline |
Lowest PSA | Palliative radiation therapy |
PFS weeks |
| 4 | 77 | 9 | Docetaxel (mCSPC) | 8.0 | 0.9 | No | N/A |
| 8 | 65 | 9 | Docetaxel (mCSPC) Enzalutamide; pulse testosterone (mCRPC) |
74.8 | 37.5 | No | 22 |
| 11 | 62 | 8 | Abiraterone, enzalutamide, nivolumab, rucaparib, docetaxel, and cabazitaxel | 605.0 | 310.3 | Yes×2 | 38 |
| 15 | 85 | 9 | Docetaxel (mCSPC) | 47.4 | 0.2 | Yes | 54+ |
| 17 | 65 | 7 | Abiraterone, enzalutamide, and radium 223 (all for mCRPC) | 319.3 | 88.6 | Yes | 44 |
mCRPC, metastatic castration-resistant prostate cancer; mCSPC, metastatic castration-sensitive prostate cancer; N/A, not available; PFS, progression-free survival; PSA, prostate-specific antigen; RT, radiation therapy.